Form 4: Biogen Director Susan Langer Reports Acquisition of 1,340 Shares
SEC Form 4 Filing
Director Susan Langer reported acquiring 1,340 shares of Biogen Inc. common stock on June 21, 2024.
Summary
- On June 21, 2024, Susan Langer, a director of Biogen Inc., acquired 1,340 shares of common stock.
- The transaction was reported on a Form 4 filing with the SEC.
- Following the transaction, Langer directly owns 2,759.1 shares of Biogen common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director purchasing shares is generally a good sign, but the impact is likely minimal.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Director stock acquisitions are common and are usually viewed as a sign of confidence in the company's prospects. However, the impact on the stock price is usually minimal unless the acquisition is very large.
Stakeholder Impact
- The acquisition could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/21/2024 | Date of transaction: Susan Langer acquired 1,340 shares of Biogen common stock. |
| 06/25/2024 | Date of report: Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.